Krimo K. Bouabdallah

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 118 publications

Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".

Response to comment on: "Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience".

Journal: Haematologica

Published: July 01, 2026

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.

Journal: British journal of haematology

Published: May 05, 2026

Single-case study of a secondary interdigitating dendritic cells sarcoma highlights the role of RAS mutation in trans-differentiation phenomenon and uncovers a potential efficacy of anti-CD19 CAR-T cell therapy.

Single-case study of a secondary interdigitating dendritic cells sarcoma highlights the role of RAS mutation in trans-differentiation phenomenon and uncovers a potential efficacy of anti-CD19 CAR-T cell therapy.

Journal: Leukemia & lymphoma

Published: November 13, 2025

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Journal: Haematologica

Published: November 06, 2025

Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.

Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.

Journal: ESMO open

Published: November 06, 2025

Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.

Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.

Journal: HemaSphere

Published: July 04, 2025

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.

Journal: Future oncology (London, England)

Published: June 19, 2025

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Journal: Blood advances

Published: June 02, 2025

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.

Journal: Haematologica

Published: April 01, 2025

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2025

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.

Journal: Blood advances

Published: December 10, 2024

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.

Journal: HemaSphere

Published: November 28, 2024

Showing 1-12 of 118

Last Updated: 09/26/2026